Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Comparison of sVEGFR-3 plasma levels at baseline and at the end of the first treatment cycle (day 28 of cycle 1) in RCC patients. Only readings that were in the assay detection range are included in this table.

From: Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

  Mean Median Range (pg/mL)
Cycle 1, Day 1 (n = 62) 71145.2 70700.0 23300 – 129200
Cycle 1, Day 28 (n = 44) 39520.5 37100.0 21500 – 64600